Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Non-Current Liabilities readings, the most recent being $7.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 0.87% year-over-year to $7.9 million, compared with a TTM value of $7.9 million through Dec 2025, down 0.87%, and an annual FY2025 reading of $7.9 million, down 0.87% over the prior year.
  • Other Non-Current Liabilities hit $7.9 million in Q4 2025 for Apellis Pharmaceuticals, up from $3.3 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $345.2 million in Q4 2021, with the low at $347000.0 in Q1 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $2.7 million (2024), compared with a mean of $64.2 million.
  • The sharpest move saw Other Non-Current Liabilities crashed 99.55% in 2022, then surged 939.01% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $345.2 million in 2021, then tumbled by 99.44% to $1.9 million in 2022, then rose by 19.3% to $2.3 million in 2023, then skyrocketed by 244.81% to $8.0 million in 2024, then fell by 0.87% to $7.9 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $7.9 million, $3.3 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.